Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Ending Cash Position: ¥482 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613

49 GF Score

Price ¥9.00

GF Value ¥5.39

Valuation Significantly Overvalued

9 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Shanghai Shenqi Pharmaceutical Investment Management Co Ending Cash Position?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 +5.14% 49 Ending Cash Position is ¥482 Mil as of Mar. 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 49/100 and a GF Value™ of ¥5.39 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position for the quarter that ended in Mar. 2026 was ¥482 Mil.

Shanghai Shenqi Pharmaceutical Investment Management Co's quarterly Ending Cash Position declined from Sep. 2025 (¥611 Mil) to Dec. 2025 (¥594 Mil) and declined from Dec. 2025 (¥594 Mil) to Mar. 2026 (¥482 Mil).

Shanghai Shenqi Pharmaceutical Investment Management Co's annual Ending Cash Position increased from Dec. 2023 (¥714 Mil) to Dec. 2024 (¥779 Mil) but then declined from Dec. 2024 (¥779 Mil) to Dec. 2025 (¥594 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Shanghai Shenqi Pharmaceutical Investment Management Co Ending Cash Position Related Terms

Shanghai Shenqi Pharmaceutical Investment Management Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co Ending Cash Position Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Ending Cash Position

Get a 7-Day Free Trial

493.74

654.57

714.29

779.39

594.09

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Ending Cash Position	Get a 7-Day Free Trial															775.21	681.53	611.09	594.09	482.37

49GF Score

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613

Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Shanghai Shenqi Pharmaceutical Investment Management Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	779.392	+	-185.301
	=	594

Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	594.091	+	-111.721
	=	482

Frequently Asked Questions Learn more about Ending Cash Position →

What does a Ending Cash Position of ¥482 Mil mean?

Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Ending Cash Position of ¥482 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.

Is Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position too high?

Shanghai Shenqi Pharmaceutical Investment Management Co's current Ending Cash Position is ¥482 Mil. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position compare to LLY and JNJ?

Shanghai Shenqi Pharmaceutical Investment Management Co's Ending Cash Position of ¥482 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Ending Cash Position for a Drug Manufacturers company?

A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Ending Cash Position mean?

A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Ending Cash Position is ¥482 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.39, compared to a current price of ¥9.00 — trading 67% above its estimated fair value. The current Ending Cash Position is ¥482 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Ending Cash Position calculated?

Ending Cash Position is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Ending Cash Position is ¥482 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be overvalued. The current stock price of ¥9.00 is trading 67% above its estimated GF Value™ of ¥5.39. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Significantly Overvalued.

Key valuation signals for SHSE:600613:

Ending Cash Position: ¥482 Mil
GF Value™: ¥5.39 vs. price of ¥9.00 (67% above fair value)
GF Score™: 49/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →